Background. Prostate specific antigen (PSA) is useful as a tumor marker for monitoring patients with prostate cancer after definitive therapy. Limitations have been noted when PSA was used for the early detection of prostate cancer. The use of prostate specific antigen density [PSAD = PSA (ng/ml)/pr
Prostate-specific antigen: Monitoring the response of carcinoma of the prostate to radiotherapy with a new tumor marker
โ Scribed by George S. Dundas; Arthur T. Porter; Peter M. Venner
- Publisher
- John Wiley and Sons
- Year
- 1990
- Tongue
- English
- Weight
- 393 KB
- Volume
- 66
- Category
- Article
- ISSN
- 0008-543X
No coin nor oath required. For personal study only.
๐ SIMILAR VOLUMES
## Background: The objective of this study was to correlate the failure pattern of localized prostate carcinoma after radiotherapy (rt) with pretreatment (pretx) psa and post-rt nadir psa, using systematic biopsies and serum psa in the assessment of outcome. ## Methods: From january 1990 to febru
## Background: It is not yet known whether screening for the detection of early prostate carcinoma will reduce mortality rates. however, data are available to assess intermediate outcomes from screening, including the performance characteristics of the screening tests and shifts in disease stage.
tients with residual tumor in 1 or more biopsies at 10 -78 months of follow-up Regional Cancer Centre, Ottawa, Ontario, Canwere selected for review. All patients had undergone biopsy on more than one ada. occasion. The 198 biopsies were stained for PSA, high molecular weight keratin,
T1, 2, 3pN0, M0), 44 patients with BPH, and 54 healthy Charite ยด, Humboldt University Berlin, Berlin, Gercontrols. Prostate volume was determined by transrectal ultrasound. many. ## RESULTS. The median values of t-PSA and f-PSA% were 7.8 mg/L and 10.5% in PCa patients, 4.3 mg/L and 20.8% in patie
The volume of the transition zone was also measured by TRUS in 134 patients.